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ABSTRACT	
	
	
The	marine	environment	is	an	abundant	and	diverse	source	of	biologically	active	
compounds,	which	have	great	potential	in	pharmaceutics	and	medicine.	Bryozoans	are	
sessile	colonial	animals	which	are	common	and	diverse	in	shallow	waters.		Despite	their	
potential	for	novel	biologically	active	secondary	metabolites,	there	have	been	very	few	
studies	on	bryozoans.	This	work	will	describe	the	isolation	and	identification	of	secondary	
metabolites	from	the	marine	bryozoan	Cryptosula	zavjalovensis,	which	belongs	to	one	of	
the	least	studied	genera	of	marine	bryozoans.	Samples	were	collected	at	the	Akkeshi	Marine	
Station,	Akkeshi,	Hokkaido,	Japan	and	were	extracted	using	ethanol.	The	ethanol	extract	
was	evaporated	to	dryness,	dissolved	in	ethyl	acetate	and	extracted	with	water	to	obtain	an	
organic	and	an	aqueous	fraction.	Preliminary	toxicity	profiling	revealed	that	the	ethyl	
acetate	extract	exhibited	cytotoxicity	toward	human	MCF7	breast	cancer	cells.	The	ethyl	
acetate	extract	was	separated	into	three	fractions	by	solid	phase	extraction	using	a	gradient	
of	methanol	and	water:	E1	80:20	v/v,	E2	100:0	v/v,	and;	E3	methanol	and	chloroform	50:50	
v/v.	Toxicity	profiling	of	these	extracts	revealed	E2	and	E3	exhibiting	toxicity	toward	human	
MCF7	breast	cancer	cells.	The	secondary	metabolites	were	isolated	using	liquid	
chromatography-mass	spectrometry	and	structures	were	determined	by	tandem	mass	
spectrometry.	
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RESUMO	
	
	
O	meio	marinho	é	uma	fonte	abundante	e	diversificada	de	compostos	biologicamente	
ativos,	que	possuem	potencial	para	produtos	farmacêuticos	e	medicamentos.	Apesar	do	seu	
potencial	para	novos	metabolitos	secundários	biologicamente	ativos,	houve	poucos	estudos	
sobre	os	briozoários.	Este	trabalho	descreve	o	isolamento	e	identificação	de	metabolitos	
secundários	do	bryozoário	marinho	Cryptosula	zavjalovensis,	que	pertence	a	um	dos	
gêneros	menos	estudados	de	bryozoários	marinhos.	As	amostras	foram	recolhidas	na	
Estação	Marítima	de	Akkeshi,	Akkeshi,	Hokkaido,	Japão	e	extraídas	com	etanol.	O	extracto	
de	etanol	foi	subsequentemente	evaporado	à	secura,	dissolvido	em	acetato	de	etilo	
extraído	com	água,	para	obter	uma	fração	orgânica	e	outra	aquosa.	O	perfil	de	toxicidade	
preliminar	revelou	que	o	extrato	de	acetato	de	etilo	exibia	citotoxicidade	em	relação	às	
células	humanas	de	câncer	de	mama	MCF7	humanas.	O	extracto	de	acetato	de	etilo	foi	
então	separado	em	três	fracções	por	extracção	em	fase	sólida	utilizando	um	gradiente	de	
metanol	e	água:	E1	80:20	v/v,	E2	100:0	v/v	e;	E3	metanol	e	clorofórmio	50:50	v/v.	O	perfil	
de	toxicidade	desses	extratos	revelou	E2	e	E3	exibindo	toxicidade	em	relação	a	células	de	
câncer	de	mama	MCF7	humanas.	Os	metabolitos	secundários	foram	isolados	utilizando	
cromatografia	líquida	e	espectrometria	de	massa	e	as	estruturas	foram	determinadas	por	
espectrometria	de	massa	em	tandem.	
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1. INTRODUCTION	
	
The	objective	of	this	work	was	to	identify	natural	products	with	potential	medicinal	
applications	from	a	type	of	bryozoan,	a	marine	organism	which	can	be	found	on	the	coast	of	
Japan.	
	
	
1.1.	The	importance	of	researching	natural	products	
	
Secondary	metabolites,	also	designated	as	natural	products,	are	organic	compounds	that	
are	produced	by	an	organism	with	no	apparent	role	for	its	growth,	development,	or	
reproduction.	The	production	of	secondary	metabolites	serves	to	adapt	the	organism	to	the	
surrounding	environment	and	to	improve	the	survival	fitness	of	an	organism	as	a	defense	
mechanism	specifically	by	exerting	physiological	effects	on	competing	organisms	(Williams,	
Stone,	Hauck,	&	Rahman,	1989).	Natural	products	have	attracted	research	interest	because	
of	its	various	applications,	particularly	in	drug	discovery.	
	
Natural	products	have	long	been	extensively	used	in	medicine	considering	that	the	earliest	
records	from	around	2600	B.C.	show	that	oils	from	Cupressus	sempevirens	(cypress),	
Glycyrrhiza	glabra	(licorice),	and	Commiphora	species	(myrrh)	were	used	to	treat	coughs,	
colds,	and	inflammation	in	Mesopotamia	(Borchardt,	2002).	Similarly,	the	use	of	natural	
products	which	were	mostly	plant-based	was	also	well-documented	in	the	Egyptian	
pharmaceutical	record,	Ebers	papyrus,	dating	1500	B.C.	in	the	form	of	gargles,	pills,	
infusions,	and	ointments	(Dias,	Urban,	&	Roessner,	2012);	in	the	Chinese	Materia	Medica	
with	the	first	record	dating	back	to	about	1100	B.C.	(Huang,	1998),	and;	in	the	Indian	
Ayurvedic	system	dating	back	from	before	1000	B.C.	(Dev,	1999).		
	
Traditionally,	natural	products	have	been	sourced	from	the	terrestrial	environment	due	to	
their	availability	and	accessibility.	Experimentation	by	trial	and	error	through	palatability	
trials	or	untimely	deaths	searching	for	treatment	to	diseases	was	a	dominant	source	of	
knowledge	for	the	use	of	natural	products	from	medicinal	plants	(Kinghorn,	2011).	Most	of	
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the	early	medicines	were	thus	based	on	these	traditional	medicines	leading	to	subsequent	
chemical,	toxicological,	pharmacological,	and	clinical	studies	(Butler,	2004).	These	
ethnopharmacological	properties	became	a	primary	source	for	medicines	for	early	drug	
discovery.	In	consequence,	the	current	uses	of	most	of	these	drugs	are	identical	or	related	
to	the	ethnopharmacological	purpose	of	the	plant-derived	natural	products	(Fabricant	&	
Farnsworth,	2001).	
	
The	success	of	plant-derived	natural	products	led	to	the	discovery	of	many	important	drugs	
such	as	the	synthesis	of	the	anti-inflammatory	agent	acetylsalicylic	acid	or	aspirin,	which	
was	derived	from	the	natural	product	salicin	extracted	from	the	bark	of	the	willow	tree	
(Salix	alba);	morphine	and	several	other	alkaloids	from	opium	poppy	(Papaver	somniferum),	
and;	anti-malarial	drug	quinine	isolated	from	the	bark	of	Cinchona	succirubra,	which	was	
traditionally	used	as	treatment	for	malaria,	fever,	malaria,	throat	diseases	and	cancer	
(DerMarderosian	&	Beutler,	2003).	
	
Aside	from	plants,	fungi	have	also	been	a	source	for	natural	products.	Aside	from	being	a	
food	source	and	its	use	in	alcoholic	beverage	preparation,	fungi	have	already	been	used	as	
medication	in	traditional	medicine	(Lorenzen	&	Anke,	1996).	Early	documented	studies	of	
natural	products	from	fungi	include	the	description	of	the	quinoid	pigments,	L-tyrosine-	and	
L-phenylalaine-derived	terphenylquinones	atromentin	and	polyporic	acid,	respectively	
(Stadler	&	Hoffmeister,	2015).	The	advancements	in	microbiology	led	to	further	use	of	fungi	
in	enzymes,	biological	control,	antibiotics	and	other	pharmacologically-active	products.	
Nevertheless,	considered	as	one	of	the	most	important	natural	product	discoveries	from	a	
fungus	is	penicillin	from	Penicillium	notatum.	Penicillin	was	a	major	turning	point,	being	one	
of	the	first	antibiotics,	rendering	a	cure	to	the	then	incurable	and	infectious	diseases.	
	
The	discovery	of	penicillin	promoted	intensive	investigation	and	paved	the	way	on	drug	
discovery	from	microbial	sources.	In	consequence,	microorganisms	have	become	a	prolific	
source	of	natural	products	and	led	to	the	discovery	of	important	products	in	the	
pharmaceutical	industry.	Some	of	these	natural	products	include	antibacterial	agents	like	
cephalosporins	from	Cephalosporium	acremonium;	immunosuppressive	agents	like	
cyclosporins	from	Trichoderma	and	Tolypocladium	species	and	rapamycin	from	
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Streptomyces	species;	cholesterol	lowering	agents	like	lovastatin	from	Aspergillus	species,	
and;	anthelmintic	and	antiparasitic	drugs	like	ivermectins	from	Streptomyces	species	(Buss,	
Cox,	&	Waigh,	2003).		
	
	
1.2.	Natural	Products	from	Marine	Organisms	
	
In	comparison,	traditional	medicine	sourced	from	the	marine	environment	had	been	very	
few	if	there	were	any	despite	the	world’s	oceans	covering	about	70%	of	earth’s	surface.	
Collecting	marine	organisms	for	obtaining	natural	products	was	limited	to	those	which	were	
easily	accessible	or	those	which	can	be	harvested	through	skin	diving.	However,	
advancements	in	technology	have	opened	the	seas	through	explorations	by	modern	
snorkeling,	scuba	diving,	manned	submersibles	and	remotely	operated	vehicles	(Dias,	
Urban,	&	Roessner,	2012).	This	resulted	in	the	realization	that	the	oceans	possess	unique	
biodiversity	which	can	be	a	viable	source	of	diverse	natural	products	with	potential	for	
pharmaceutics	(Haefner,	2003).		
	
The	heightened	interest	in	investigating	the	marine	environment	led	to	the	discovery	of	
thousands	of	new	natural	products.	Recently,	there	have	been	more	than	a	thousand	new	
compounds	being	discovered	and	reported	annually	(Blunt,	Copp,	Keyzers,	Munro,	&	
Prinsep,	2016).		This	demonstrates	that	the	marine	environment	is	an	abundant	and	diverse	
source	of	biologically	active	compounds,	some	of	which	are	novel	chemical	classes	not	
found	in	terrestrial	sources	(Cragg	&	Newman,	2013).		These	compounds	were	found	to	
have	potential	for	pharmaceutics	and	medicine,	particularly	as	anti-cancer	agents.	The	first	
approved	drug	derived	from	a	marine	product	called	ziconotide	(Mathur,	2000)	was	a	non-
narcotic	analgesic,	espite	the	focus	on	potential	anti-cancer	drugs.	It	was	isolated	as	a	
constituent	of	the	venom	from	tropical	cone	snails	of	the	genus	Conus	(Bulaj,	et	al.,	2003).	
	
Despite	being	scarce	in	vertebrates	(Jha	&	Zi-rong,	2004),	natural	products	have	been	
abundantly	obtained	from	other	marine	organisms	such	as	algae,	sponges,	cnidarians,	
bryozoans,	mollusks,	tunicates,	echinoderms,	marine	microorganisms	and	phytoplankton,	
		 4	
mangroves	and	other	intertidal	plants	and	microorganisms.	The	trend	however,	is	that	
research	efforts	on	the	search	of	marine	natural	products	are	directed	towards	marine	
microorganisms,	accounting	for	most	of	the	new	secondary	metabolites	from	the	marine	
environment	in	recent	years	(Blunt,	Copp,	Keyzers,	Munro,	&	Prinsep,	2016).	Antibiotic,	
antifungal,	antiviral,	and	antiyeast	activities	of	the	marine	microorganisms	have	been	
reported	(Buck,	Meyers,	&	Kamp,	1962).				
	
Recent	natural	products	isolated	from	marine	microorganisms	include	cyanogramide,	an	
unprecedented	spirocyclic	alkaloid	with	multidrug-resistance	reversing	activity,	isolated	
from	Actinoalloteichus	cyanogriseus	(Fu,	Kong,	Li,	Wang,	&	Zhu,	2014);	two	new	aplysiatoxin	
analogues,	3-methoxyaplysiatoxin	and	3-methoxydebromoaplysiatoxin	isolated	from	
Trichodesmium	erythraeum	inhibited	the	Chikungunya	virus	(Gupta,	et	al.,	2014),	and;	
belizentrin,	a	novel	and	structurally	unique	macrolide	obtained	from	Prorocentrum	
belizeanum,	which	had	potent	effects	to	neuronal	network	integrity	eventually	resulting	to	
cell	death	(Domínguez,	et	al.,	2014).		
	
Algae	have	also	been	one	of	the	prolific	sources	of	natural	products	from	the	marine	
environment.	Some	of	the	recent	natural	products	isolated	from	marine	algae	include	a	new	
diketosteroid,	(E)-stigmasta-24(28)-en-3,6-dione,	isolated	from	the	green	alga	Tydemania	
expeditionis	had	moderate	inhibitory	activities	against	prostate	cancer	cells	(Zhang,	et	al.,	
2012);	spiralisones	A-D	isolated	from	the	Australian	marine	brown	alga	Zonaria	spiralis	
exhibited	promising	kinase	inhibitory	and	antibacterial	activity	(Zhang,	Xiao,	Conte,	Khalil,	&	
Capon,	2012),	and;	a	novel	bromophenol,	5,5”-oxybis(methylene)bis(3-bromo-4-(2’,3’-
dibromo-4’,5’-dihydroxylbenzyl)benzene-1,2-diol),	isolated	from	the	red	alga	Vertebrata	
lanosa	had	cellular	antioxidant	activities	(Olsen,	Hansen,	Isaksson,	&	Andersen,	2013). 
	
Sponges	have	also	been	a	dominant	source	of	new	secondary	metabolites	although	there	is	
a	growing	realization	that	these	bioactive	metabolites	might	have	been	produced	by	
microbial	symbionts	thereby	requiring	further	analyses	on	sponge	matrices	(Blunt,	Copp,	
Keyzers,	Munro,	&	Prinsep,	2016).	Moreover,	numerous	new	bioactive	metabolites	have	
also	been	isolated	from	cnidarians,	mollusks,	tunicates,	and	echinoderms.	However,	despite	
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its	potential	for	novel	natural	products,	there	have	been	very	few	studies	on	secondary	
metabolites	from	bryozoans	(Blunt,	Copp,	Munro,	Northcote,	&	Prinsep,	2004).		
	
	
1.3.	Bryozoans	
	
Bryozoans	are	invertebrates	that	can	be	both	found	in	freshwater	and	marine	
environments,	particularly	in	shallow	areas.	Most	of	the	known	bryozoans	are	marine	
bryozoans	and	are	found	in	coastal	waters	attached	to	rocks,	pilings,	shells,	algae,	and	other	
animals.	On	the	other	hand,	the	taxonomic	diversity	of	freshwater	bryozoans	is	rather	low	
(Hayward	&	Ryland,	1985).		
	
Phylum	Bryozoa	(Figure	1.1)	is	mostly	diverse,	probably	exceeding	8000	living	species	with	a	
good	fossil	record	dating	back	to	the	Ordovician	showing	they	are	relatively	unchanged	in	
the	past	ca.	480	million	years	(Fortunato,	2015).	Examples	of	bryozoans	can	be	seen	in	
Figure	1.2	and	Figure	1.3.		
	
Figure	1.1	The	Tree	of	Life,	showing	Phylum	Bryozoa	in	Kingdom	Animalia	(adapted	from	www.greennature.ca).	
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Figure	1.2	A	small	Bugula	neritina	colony	from	San	Francisco	Bay,	USA.	The	light	tan	organism	on	the	left	is	another	species	
of	Bugula	while	red-orange	organism	below	it	is	another	bryozoan	species,	Watersipora	subtorquata(Solórzano,	2011).	
	
	
Figure	1.3	A	colony	of	Watersipora	subtorquata,	mainly	red	with	a	blackened	center,	encrusting	under	an	intertidal	rock	in	
San	Francisco	Bay,	USA.		On	the	lower	left	is	another	bryozoan,	Schizoporella	unicornis	(Cohen,	2011).		
	
Bryozoans	are	sometimes	referred	to	as	moss	animals	and	are	tiny,	sessile,	colonial	animals.	
They	have	a	distinguishing	specialized	feeding	structure	called	a	lopophore	which	is	either	a	
horseshoe-	or	circular-shaped	tentacle	structure	extension	of	the	body	wall	that	surrounds	
the	mouth.	The	basic	body	plan	of	a	bryozoan	consists	of	a	polyp	protected	by	a	gelatinous	
or	calcareous	enclosure	called	a	zooid.		
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These	zooids	may	then	integrate	to	form	a	colony.	Bryozoan	colonies	can	be	encrusting	
(Figure	1.4),	wherein	flat	and	delicately	lacy	crusts	are	formed;	arborescent	(Figure	1.5),	
wherein	colonies	can	be	erect,	branching,	and	tree-like,	or;	even	free	living.	Due	to	these	
features,	bryozoan	colonies	have	often	been	mistaken	as	hydroids,	corals,	or	seaweeds.	
While	some	bryozoan	colonies	encrust	rocks,	pilings,	and	algae,	some	are	known	to	grow	on	
the	bottom	of	ships	which	results	to	the	fouling	of	ships	causing	drag	and	reducing	
efficiency	and	maneuverability.		
	
The	morphological	features	of	bryozoans	had	been	historically	the	bases	for	taxonomy	
(Ruppert	&	Barnes,	1994).	However,	bryozoan	taxonomy	is	continually	revised	and	the	
taxonomic	groupings	does	not	necessarily	represent	the	phylogenetic	relationships	between	
species	(Sharp,	Winson,	&	Porter,	2007).		
	
	
	
	
	
	
	
	
Figure	1.4	Sketch	of	an	arborescent	bryozoan	(Smithsonian	Marine	Station	at	Fort	Pierce,	2016).	
	
	
	
	
	
	
	
	
	
Figure	1.5	Sketch	of	an	encrusting	bryozoan	(Smithsonian	Marine	Station	at	Fort	Pierce,	2016).	
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Phylum	Bryozoa	is	classified	further	into	three	major	classes:	class	Phylactolaemata	
exclusively	contains	freshwater	bryozoans;	class	Stenolaemata	are	exclusively	marine	
bryozoans,	with	only	one	order	with	remaining	living	species,	order	Cyclostomata,	while	the	
rest	are	fossil	species,	and;	class	Gymnolaemata	is	a	mostly	marine	class	containing	two	
orders,	Cheilostomata	and	Ctenostomata.	The	three	orders	mentioned	have	been	reported	
to	have	natural	products	and	biological	activity	(Sharp,	Winson,	&	Porter,	2007).				
	
	
1.4.	Natural	Products	from	Bryozoans	
	
Most	of	the	metabolites	isolated	from	bryozoans	have	been	alkaloids	(Blunt,	Copp,	Munro,	
Northcote,	&	Prinsep,	2004).		Some	of	the	metabolites	obtained	are	macrolide	lactones,	
indole	alkaloids,	isoquinoline	quinones,	sterols	and	other	carbohydrates	with	a	heteroatom	
such	as	nitrophenols	and	disulfides	(Sinko,	Rajchard,	Balounova,	&	Fikotova,	2012).		
	
In	terms	of	chemical	ecology,	one	of	the	most	studied	bryozoan	species	is	Bugula	neritina,	
from	which	bryostatins,	a	promising	anticancer	metabolite	with	significant	biological	
activities,	have	been	isolated	(Pettit,	Herald,	Doubek,	&	Herald,	1982).	Upon	the	isolation	
and	the	elucidation	of	the	structure	of	bryostatin-1	(Figure	1.6),	there	had	been	numerous	
studies	exploring	its	antitumor	and	anticancer	potential.		
	
	
Figure	1.6	The	structure	of	bryostatin-1.	
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Bryostatin	1,	a	macrocyclic	lactone	and	a	protein	kinase	C	activator,	have	undergone	Phase	I	
clinical	study	in	patients	with	advanced	cancer	to	obtain	a	safe	dosage	although	side	effects	
included	myalgia	(Prendiville,	et	al.,	1993).	When	bryostatin	1	was	administered	to	patients	
with	advanced	malignancies	in	prolonged	infusion	schedules,	there	had	been	limited	clinical	
activity	observed	and	it	was	suggested	for	future	studies	to	combine	it	with	other	cytotoxics	
or	targeted	therapies	(Marshall,	et	al.,	2002).	A	Phase	II	clinical	study	combined	bryostatin	1	
with	cisplatin	but	the	toxicity	profile,	primarily	severe	myalgias,	precludes	tolerability	
thereby	preventing	any	further	investigation	using	this	combination	(Morgan,	et	al.,	2012).	
	
Despite	B.	neritina	being	a	single	species,	the	natural	products	isolated	vary	among	
populations.	That	is,	different	populations	of	B.	neritina	produce	different	bryostatins	
(Davidson	&	Haygood,	1999).	However,	it	was	subsequently	discovered	that	bryostatins	are	
produced	by	a	bacterial	symbiont,	Endobugula	sertula.	E.	sertula	is	a	unique	bacterial	
symbiont	of	B.	neritina	and	produces	bryostatins	which	protect	B.	neritina	larvae	against	
predation	from	fish	(Lopanik,	Lindquist,	&	Targett,	2004).	These	results	show	a	different	
perspective	on	natural	products	from	bryozoans,	which	should	consider	the	variable	
presence	of	symbionts	and	the	environmental	factors	with	which	these	metabolites	are	
produced.		
	
The	bryozoan,	Flustra	foliacea	has	yielded	several	brominated	alkaloids	(Figure	1.7)	
including	flustramine	A	and	B	(Carle	&	Christophersen,	1980),	flustramine	C,	flustraminol	A	
and	B	(Carle	&	Christophersen,	1981)	flustramide	A	(Wulff,	Carle,	&	Christophersen,	1982),	
and	dihydroflustramine	C,	which	had	strong	activity	against	Bacillus	subtilis	(Wright,	1984).		
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Figure	1.7	Structures	of	a.	flustramine	A,	b.	flustramine	B,	c.	flustramine	C,	d.	flustraminol	A,	e.	flustraminol	B,	f.	flustramide	
A,	and	g.	dihydroflustramine	C.	
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Alkaloids	(Figure	1.8)	from	the	bryozoan	Pterocella	vesiculosa	have	also	been	isolated.	These	
include	pterocellin	A	and	B	(Yao,	Prinsep,	Nicholson,	&	Gordon,	2003)	with	pterocellin	A	
exhibiting	potent	antitumor	activity	towards	murine	leukemia	cell	line	(Wang,	Prinsep,	&	
Martinus,	2016);	pterocellins	C-F	(Prinsep,	2008),	and;	5-bromo-8-methoxy-1-methyl-β-
carboline	(Till	&	Prinsep,	2009).	
	
	
	
	
Figure	1.8	Structures	of	a.	pterocellin	A,	b.	pterocellin	B,	c.	pterocellin	D,	d.	pterocellin	C,	e.	pterocellin	E,	f.	pterocellin	F,	and	
g.	5-bromo-8-methoxy-1-methyl-β-carboline.	
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Although	not	as	common,	two	nitrophenols,	desmethylphidolopin	and	3-nitro-4-
hydroxybenzyl	alcohol	(Figure	1.9),	have	been	isolated	from	the	northeast	Pacific	bryozoan	
Phidolopora	pacifica	(Tischler,	Ayer,	&	Andersen,	1986).	
	
	
Figure	1.9	Structures	of	a.	desmethylphidolopin	and	b.	3-nitro-4-hydroxybenzyl	alcohol.	
	
Bugula	neritina,	Flustra	foliacea,	Pterocella	vesiculosa,	and	Phidolopora	pacifica	are	marine	
bryozoans	that	belong	to	the	class	Gymnolaemata	and	order	Cheilostomata,	one	of	the	
three	orders	of	bryozoans	where	secondary	metabolites	have	been	reported	(Sharp,	
Winson,	&	Porter,	2007).		
	
	
1.5.	Cryptosula	zavjalovensis	
	
One	of	the	least	studied	genera	of	bryozoans	is	genus	Cryptosula,	which	is	classified	under	
the	same	order	Cheilostomata	as	shown	in	Error!	Reference	source	not	found..	Currently,	
there	are	only	five	recorded	species	under	this	genus.	The	first	recorded	species	is	
Cryptosula	pallasiana,	originally	classified	as	Eschara	pallasiana,	and	is	cosmopolitan	with	
worldwide	distribution.	Worldwide	distribution	of	bryozoans,	as	with	other	fouling	species,	
is	suggested	to	have	come	from	ships	and	may	develop	to	be	invasive	species,	particularly	in	
ports	and	harbors	(Almeida,	Souza,	Gordon,	&	Vieira,	2015).	
	
Bryozoans	under	the	genus	C.	pallasiana	are	encrusting.	The	overall	color	of	C.	pallasiana	
colonies	is	white,	orange,	or	pink.	The	aperture	of	C.	pallasiana	is	often	described	as	bell-
shaped.	C.	pallasiana	has	no	spines,	no	avicularia	which	are	jaw-like	structures	that	opens	
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and	closes,	and	no	ovicells	for	brooding	embryos,	all	of	which	are	conspicuous	features	in	
many	bryozoans.	
	
A	recent	study	determined	the	chemical	constituents	of	C.	pallasiana	from	which	seven	
alkaloids	were	isolated	(Figure	1.8	a-g),	of	which	two	are	new	natural	products,	p-
methylsulfonylmethyl-phenol	(Figure	1.8	f)	and	7-bromo-2,4-(1H,3H)-quinazolineione	
(Figure	1.8	g),	with	p-methylsulfonylmethyl-phenol	exhibiting	strong	cytotoxicity	against	
leukemia	cell	line	(Tian,	et	al.,	2014).	
	
	
	
	
Figure	1.10	Structures	of	a.	aldisin,	b.	2-bromoaldisin,	c.	6-bromoindole-3-carbaldehyde,	d.	indole-3-carboxyaldehyde,	e.	
indole-3-oxoacetamide,	f.	2,4(1H,3H)-quinazolinedione,	and	g.	7-bromo-2,4(1H,3H)-quinazolinedione,	with	some	pertinent	
properties.	
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Cryptosula	zavjalovensis	may	be	difficult	to	differentiate	from	C.	pallasiana.	C.	zavjalovensis	
colonies	are	also	encrusting	and	have	a	similar	orange	color.	However,	inspection	under	a	
microscope	shows	that	C.	zavjalovensis	(Figure	1.11)	has	a	distinct	zooid	structure.	This	
difference	is	even	clearer	upon	inspection	under	a	scanning	electron	microscope.		
	
		
	
	
	
	
	
	
	
	
Figure	1.11	A	scanning	electron	microscope	image	of	a.	Cryptosula	pallasiana	and	b.	Cryptosula	zavjalovensis	(Bock,	2009).	
	
Moreover,	C.	zavjalovensis	emits	a	lemon-like	odor	upon	close	inspection.	This	may	be	
hypothesized	to	be	emitted	as	part	of	a	defense	mechanism	from	predators.	It	is	therefore	
of	interest	to	investigate	the	natural	products	produced	by	C.	zavjalovensis,	which	may,	
directly	or	indirectly,	justify	such	a	defense	mechanism.		
	
Aside	from	the	study	mentioned,	research	on	Cryptosula	is	considerably	scarce,	more	so	on	
C.	zavjalovensis	which	is	not	as	globally	distributed	as	C.	pallasiana.	C.	zavjalovensis	have	
been	reported	in	North	Pacific	locations	such	as	Vladivostok,	Russia;	Alaska,	U.S.A.	(Dick,	
Grischenko,	&	Mawatari,	2005)	and;	Hokkaido,	Japan	(Grischenko,	Dick,	&	Mawatari,	2007).
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	 	 Figure	1.12	Taxonomy	of	the	bryozoan	species:	Bugula	neritina,	Flustra	foliacea,	Pterocella	vesiculosa,	Phidolopora	pacifica,	and	Cryptosula	zavjalovensis.
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1.6.	Objectives	and	Methodology	
	
The	aim	of	this	work	has	been	to	isolate	and	identify	natural	products	from	Cryptosula	
zavjalovensis.	While	pursuing	this	objective,	samples	were	collected	from	the	coast	of	
Hokkaido,	Japan,	separated	into	fractions	by	solvent	extraction,	solid	phase	extraction	and	
chromatography,	and	finally	analysis	by	LC-MS.	
	
1.6.1.	Separation	by	Solvent	Extraction		
	
Extraction	of	the	natural	products	from	Cryptosula	zavjalovensis	was	done	using	solvent	
extraction.	Solvent	extraction	or	liquid-liquid	extraction	is	a	method	to	separate	a	
compound	which	relies	on	the	solubility	of	the	components.	This	technique	is	widely	used	in	
the	laboratory	for	refining,	isolating,	and	purifying	compounds.		
In	this	study,	the	organic	phase	of	the	extract	was	separated	using	ethyl	acetate	and	the	
aqueous	phase	using	water.	This	is	a	rough	separation	of	the	components	of	the	extract	
where	the	hydrophilic	natural	products	will	be	in	the	aqueous	layer	while	the	hydrophobic	
natural	products	will	be	in	the	organic	layer.	To	enhance	this	separation,	this	process	was	
repeated	for	the	separated	organic	and	aqueous	layers.	
	
	
1.6.2.	Solid	Phase	Extraction	and	Reversed-Phase	Chromatography	
	
The	extract	obtained	from	the	organic	layer	was	further	separated	by	means	of	solid	phase	
extraction	(SPE).	SPE	was	used	to	separate	the	different	classes	of	compounds	by	their	
polarity,	thereby	separating	the	more	polar	to	non-polar	compounds	into	different	
fractions.	
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Figure	1.13	An	example	of	a	solid	phase	extraction	(Waters,	2017)	
	
SPE	is	a	form	of	step-wise	chromatography	designed	to	partition	the	components	in	a	liquid	
phase	sample	onto	a	stationary	phase	of	either	a	sorbent	or	resin.	Figure	10	shows	how	SPE	
can	separate	the	sample	into	its	different	components.		
	
As	the	components	in	the	organic	layer	are	hydrophobic,	reversed-phase	SPE	was	done	to	
fractionate	the	components	because	it	retains	most	components	having	hydrophobic	
properties.	Reversed-phase	SPE	utilizes	a	non-polar	stationary	phase	and	a	polar	mobile	
phase.	The	study	used	silica-based	sorbent	in	a	cartridge	as	the	stationary	phase	and	a	step-
gradient	of	methanol	as	the	mobile	phase	to	fractionate	the	organic	extract	based	on	
hydrophobicity.	That	is,	the	most	polar	components	of	the	sample	were	eluted	first.		
	
In	a	similar	process,	the	extract	obtained	from	the	aqueous	layer	was	further	separated	
using	reversed-phase	chromatography.	Reversed-phase	chromatography	utilizes	a	
hydrophobic	stationary	phase	and	a	polar	mobile	phase.	Octadecyl	(C18)	silica	gel	contained	
in	a	column	was	used	as	the	stationary	phase	and	a	step-gradient	of	methanol	as	the	mobile	
phase	to	fractionate	the	aqueous	extract.	This	also	resulted	to	the	more	hydrophilic	
components	of	the	sample	being	eluted	first.		
	
Fractionation	of	the	organic	and	aqueous	extracts	using	solid	phase	extraction	and	reversed-
phase	chromatography,	respectively,	served	as	sample	preparation	prior	to	liquid	
chromatography	and	mass	spectrometry.			
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1.6.3.	Analysis	by	Liquid	Chromatography-Mass	Spectrometry	(Electrospray	Ionization)	
	
The	fractions	obtained	were	further	separated	in	a	liquid	chromatography-mass	
spectrometry	(LC-MS)	system.	Columnar	liquid	chromatography,	specifically	high-
performance	liquid	chromatography	(HPLC),	was	utilized.	HPLC	employs	liquid	mobile	and	
stationary	phases.	The	mobile	phase	solvents	together	with	the	samples	were	forced	
through	a	tightly	packed	column	containing	a	thin	film,	made	of	small	particles	with	
molecules	bonded	to	their	surface,	having	liquid-like	properties.	In	the	study,	an	
octadecylsilyl	(ODS)	column	with	3	µm	silica	particles	was	used	as	the	stationary	phase	and	a	
gradient	of	acetonitrile	and	water	as	the	mobile	phase.		
	
	
Figure	1.14	Components	of	a	basic	High-Performance	Liquid	Chromatography	(HPLC)	System	(Waters,	2017).	
	
Typically,	a	detector	at	the	end	of	the	column	monitors	the	separated	components	of	the	
sample.	The	electrical	signals	from	the	detector	are	translated	into	chromatograms,	which	
enable	to	identify	and	quantify	the	concentration	of	the	components.	However,	it	might	be	
difficult	to	ascertain	if	a	certain	peak	is	pure	and	contains	only	a	single	chemical.		
	
Coupling	the	HPLC	with	mass	spectrometry	helps	identify	these	peaks	as	it	tells	the	masses	
of	the	chemicals	present	in	every	peak.	Thus,	after	separation	of	the	components	from	
HPLC,	these	components	enter	the	mass	spectrometer	to	be	ionized.	The	ions	formed	are	
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accelerated	into	the	mass	analyzer,	where	the	ions	are	subjected	to	electric	and	magnetic	
field	to	alter	their	paths	thereby	separating	the	ions	depending	on	their	mass-to-charge	
(m/z)	ratios.	A	detector	at	the	end	of	the	mass	analyzer	measures	the	intensity	of	the	ionic	
beam.	This	is	then	translated	into	a	chromatogram	of	the	ionic	beam	intensity	as	a	function	
of	the	mass-to-charge	ratio	of	each	ionic	component.	Moreover,	quantitative	analysis	can	
be	done	to	determine	the	concentration	of	the	component	by	relating	it	to	the	height	of	the	
mass	spectrometric	peak.		
	
In	the	study,	electrospray	ionization	served	the	ion	source	of	the	LC-MS	system.	
Components	separated	from	the	HPLC	were	bombarded	with	ions	or	were	collided	with	
other	ions	to	produce	ions	for	mass	spectrometric	analysis.	Electrospray	ionization	uses	
electrical	energy	to	assist	the	transfer	of	ions	from	solution	into	the	gaseous	phase	prior	to	
mass	spectrometric	analysis.	Thus,	ionic	species	in	the	sample	can	be	analyzed	with	
increased	sensitivity.	Moreover,	neutral	compounds	can	be	converted	to	ionic	form	in	
solution	or	in	gaseous	phase	by	protonation	or	cationization	(Ho,	et	al.,	2003).		
	
	
Figure	1.15	Electrospray	ionization	mechanism	(Ho,	et	al.,	2003).	
	
ESI	can	ionize	very	fragile	biomolecules	and	detect	non-covalent	complexes	with	no	
dissociation.	In	addition,	it	can	analyze	large	biomolecules	in	a	small	mass-to-charge	ratio	
range.	This	feature	is	advantageous	particularly	in	identifying	novel	or	unknown	compounds	
or	natural	products,	as	in	the	case	of	this	research.	
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2. EXPERIMENTAL	SECTION	
	
2.1.	General	Experimental	Procedures	
	
The	ethanol,	methanol,	chloroform,	ethyl	acetate,	acetonitrile,	and	formic	acid	used	were	
procured	from	SIgma-Aldrich	(Japan)	and	Carlo	Erba	Reagents	(Portugal).	All	the	reagents	
used	were	analytical	or	HPLC	grade	and	used	without	further	purification.	In	Japan,	the	
liquid	chromatography-mass	spectrometry	(LC-MS)	analyses	at	were	done	using	an	Agilent	
1100	Series	HPLC	System	coupled	with	a	Bruker	Daltonics	micrOTOF-HS	mass	spectrometer	
(ESI).	In	Portugal,	the	liquid	chromatography-mass	spectrometry	(LC-MS)	and	tandem	mass	
spectrometry	(MS/MS)	analyses	were	done	using	a	Bruker®	QqTOF	Impact	II	Mass	
Spectrometer	with	ESI	and	CaptiveSpray	nanoBooster™	with	a	ThermoScientific™	Dionex™	
UltiMate™	WPS-3000TPL	RSLCnano	autosampler.		
	
	
Figure	2.1	A	process	flow	diagram	of	the	methodology.	
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2.2.	Sample	Collection	
	
Samples	of	Cyrptosula	zavjalovensis	(60	g)	were	collected	at	the	Akkeshi	Marine	Station,	
Hokkaido,	Japan	(Figure	2.2)	during	low	tide	in	August	2016,	with	tide	heights	at	0.2	to	0.4	
m.	Collection	was	done	in	two	locations	by	the	pier	of	the	marine	station	(Figure	2.3):	1	at	
the	first	piling	of	the	pier	and	2	by	the	rocks	at	the	end	of	the	pier.	The	samples	were	
collected	from	algae	and	rocks	where	the	bryozoan	colonies	have	encrusted.	Algae	with	
encrusting	bryozoans	were	cut	and	bryozoans	in	rocks	were	scraped	and	were	placed	in	
containers	with	seawater	and	were	brought	to	the	marine	laboratory	for	separation.	The	
bryozoan	samples	were	delicately	separated	and	removed	from	the	algae	and	rocks	using	
forceps.	Foreign	particles	in	the	samples	were	also	removed.	The	bryozoan	samples	
collected	were	inspected	under	a	compound	light	microscope	(Olympus)	for	zooid	structure	
and	C.	zavjalovensis	samples	were	separated.	These	samples	also	emitted	a	lemon-like	odor,	
which	is	distinct	to	the	species.		
	
	
Figure	2.2	Location	of	Akkeshi	in	the	island	of	Hokkaido,	Japan	(Google,	2017).	
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Figure	2.3	The	sampling	locations	at	the	1	first	piling	and	2	by	the	rocks	of	the	pier	of	the	Akkeshi	Marine	Station,	Hokkaido,	
Japan	(Google,	2017).	
	
	
The	C.	zavjalovensis	samples	were	weighed	and	placed	in	vials	containing	10	g	of	sample	
each	vial.	Each	vial	was	filled	with	ethanol	(30mL)	to	store	the	samples	for	transport	to	the	
laboratory	in	Hokkaido	University	(Hokudai),	Sapporo,	Japan	and	University	of	Algarve	
(UAlg),	Faro,	Portugal.	Vials	were	kept	in	a	freezer	(-15	°C)	until	analysis.	
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Figure	2.4	Optical	microscopy	image	from	a	sample	of	Cryptosula	zavjalovensis,	showing	its	characteristic	zooid	structure.	
	
	
2.3.	Preliminary	Tests	at	Hokkaido	University	
	
Preliminary	tests	were	conducted	at	the	Okino	Laboratory,	Faculty	of	Environmental	Earth	
Science,	Hokkaido	University,	Sapporo,	Japan.	These	tests	were	done	to	determine	the	
presence	and	bioactivity	of	the	secondary	metabolites	from	Cryptosula	zavjalovensis.	
	
	
2.3.1.	Solvent	Extraction	
	
The	sample	was	homogenized	by	mashing	using	a	mortar	and	pestle.	The	sample	was	then	
filtered	using	vacuum	filtration	and	was	washed	with	ethanol	(100mL)	three	times.	The	
ethanol	was	removed	from	the	filtrate	by	means	of	a	rotary	evaporator	to	obtain	a	crude	
extract	(340	mg).		
	
The	crude	extract	was	then	partitioned	into	an	organic	and	aqueous	fraction	using	ethyl	
acetate	(100	mL)	and	Milli-Q®	water	(100	mL),	respectively.	This	was	done	three	times	to	
obtain	better	separation	between	the	two	fractions.	The	organic	and	aqueous	fractions	
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were	dried	using	a	rotary	evaporator	to	obtain	an	ethyl	acetate	(EtOAc)	extract	(21.3	mg)	
and	Milli-Q®	water	(H2O)	extract	(300	mg),	respectively.			
	
	
2.3.2.	Solid	Phase	Extraction	and	Reversed-Phase	Chromatography	
	
The	EtOAc	extract	was	fractionated	by	solid	phase	extraction	using	a	Strata®	SPE	to	obtain	
three	fractions:	a	gradient	of	methanol	(MeOH)	and	H2O,	E1	80:20,	E2	100:0	v/v,	and;	E3	
methanol	and	chloroform	50:50	v/v.	The	wash	and	elution	volume	used	was	4	mL.		
	
The	aqueous	extract	was	fractionated	by	reversed-phase	chromatography	using	octadecyl	
(C18)	as	a	stationary	phase	with	a	gradient	composed	of	MeOH	and	H2O	to	obtain	four	
fractions:	H1	0:100,	H2	30:70,	H3	60:40,	H4	100:0	v/v.	The	wash	and	elution	volume	used	
was	6	mL,	which	was	thrice	the	depth	volume	for	the	stationary	phase	to	be	totally	
submerged.		
	
The	extracts	were	dried	using	a	rotary	evaporator	and	were	weighed	and	placed	in	pre-
weighed	vials	prior	to	liquid	chromatography-mass	spectrometry	(LCMS)	and	cytotoxicity	
sample	preparation	and	for	storage.		
	
	
2.3.3.	Cytotoxicity	Screening	
	
Cytotoxicity	was	evaluated	using	MTT	(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium	bromide)	assay.	In	the	mitochondria	of	living	cells,	MTT	is	reduced	to	formazan	
as	shown	in	Figure	2.4.	Formazan	crystals,	which	are	purple	in	color,	are	dissolved	in	
dimethyl	sulfoxide	(DMSO)	and	the	optical	density	is	measured	at	570	nm.		
		 25	
	
Figure	2.5	The	reduction	of	MTT	into	formazan.	
	
MTT	was	dissolved	in	Dulbecco’s	phosphate	buffered	saline	(DPBS)	at	a	concentration	of	5	
mg/mL	and	was	frozen	at	–20	°C	until	use.	The	wells	of	the	plate	were	seeded	with	90	µL	of	
the	cell	suspension	to	make	a	concentration	of	1	x	104	cells	per	well.	MCF-7	breast	cancer	
cell	line	(Culture	Collections,	Public	Health	England)	was	used	in	the	analysis.	After	a	24-hour	
incubation,	10	µL	of	the	samples	were	added	at	a	concentration	of	1	µg/mL	and	10	µg/mL.	
Cisplatin	was	used	as	a	positive	control.		
	
Incubation	was	done	for	72	hours.	After	incubation,	the	medium	was	aspirated	from	the	
plate.	The	healthy	cells	should	have	adhered	at	the	bottom	of	the	well.	MTT	solution	(100	
µL)	was	added	to	each	well	was	incubated	for	3	hours.	Healthy	cells	manifested	purple	
formazan	crystals.	The	MTT	solution	was	then	aspirated	and	DMSO	(100	µL)	was	added	to	
dissolve	the	formazan	crystals.	This	was	then	incubated	for	10	minutes	at	37	°C	and	shaken	
or	10s	before	it	was	read	under	Thermo	Labsystems	Multiskan	JX	plate	reader	at	an	
absorbance	of	570	nm.		
	
The	cytotoxicity	effect	is	calculated	as:	%"#$$	"&'('()*+	,--#+' = 	 1 − 12'*+3$	4#56*'&	(-	'7#3'#4	+#$$612'*+3$	4#56*'&	(-	+(5'7($	+#$$6 ×100	
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2.3.4.	Liquid	Chromatography-Mass	Spectrometry	
	
Each	extract	obtained	was	diluted	in	filtered	ethanol	to	obtain	a	concentration	of	100	µg/mL	
filtered	ethanol	for	LCMS	analysis.	500	µL	of	each	sample	solution	was	placed	in	an	LCMS	
vial	for	analysis.				
	
The	LCMS	system	was	calibrated	using	an	ESI	tuning	mix	solution:	570	µL	acetonitrile	
(MeCN),	30	µL	Milli-Q®	water,	and	20	µL	ESI	tuning	mix	solution.	For	the	analyses	of	the	
EtOAc	extracts,	the	HPLC	system	was	equipped	with	a	Cadenza®	CD-C18	column	(2	x	
150mm,	3µm,	25°C,	0.2	mL/min)	under	the	following	conditions:	0-15	min,	gradient	elution	
of	50-80%	MeCN	with	0.1%	(v/v)	formic	acid	in	H2O;	15-30	min,	isocratic	elution	of	80%	
MeCN	with	0.1%	(v/v)	formic	acid	in	H2O.	Samples	were	analyzed	in	both	positive	and	
negative	ionization	methods.		
	
For	the	analyses	of	H2O	extracts,	the	HPLC	system	was	equipped	with	a	Cosmosil	HILIC®	
column	(4.6	x	250mm,	5µm,	type	Waters,	25°C,	0.2	mL/min)	under	the	following	conditions:	
0-30	min,	gradient	elution	of	10-80%	MeCN	with	0.1%	(v/v)	formic	acid	in	H2O;	30-35	min,	
isocratic	elution	of	80%	MeCN	with	0.1%	(v/v)	formic	acid	in	H2O.	Samples	were	analyzed	in	
both	positive	and	negative	ionization	methods.		
	
Post-processing	of	the	chromatograms	was	done	using	HyStar®.	Potential	peaks	were	noted	
and	matched	in	the	MarinLit®	database,	an	extensive	database	of	marine	natural	products,	
for	possible	identification.	
	
	
2.4.	Analyses	at	the	University	of	Algarve	
	
Samples	were	brought	to	the	University	of	Algarve	for	further	analyses.	Preliminary	tests	
results	obtained	from	Hokkaido	University	helped	develop	the	tests	done	at	UAlg.	Since	the	
bioactive	compounds	were	present	in	the	organic	extracts,	extraction	and	analyses	done	
were	focused	on	the	organic	extracts.		
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2.4.1.	Solvent	Extraction	
	
The	sample	was	homogenized	by	mashing	using	a	mortar	and	pestle.	The	sample	was	then	
filtered	using	vacuum	filtration	and	was	washed	with	ethanol	(100mL)	three	times.	The	
ethanol	was	removed	from	the	filtrate	by	means	of	a	rotary	evaporator	to	obtain	a	crude	
extract	(186	mg).		
	
The	crude	extract	was	then	partitioned	into	an	organic	and	aqueous	fraction	using	ethyl	
acetate	(100	mL)	and	Milli-Q®	water	(100	mL),	respectively.	This	was	done	three	times	to	
obtain	better	separation	between	the	two	fractions.	The	organic	fraction	was	dried	using	a	
rotary	evaporator	to	obtain	an	ethyl	acetate	(EtOAc)	extract	(60	mg).	
	
	
2.4.2.	Solid	Phase	Extraction	
	
The	EtOAc	extract	was	fractionated	by	solid	phase	extraction	using	a	Strata®	SPE	to	obtain	
three	fractions:	a	gradient	of	methanol	(MeOH)	and	H2O,	E1	80:20,	E2	100:0	v/v,	and;	E3	
methanol	and	chloroform	50:50	v/v.	The	elution	volume	used	was	4	mL.		
	
The	fractions	were	dried	using	a	rotary	evaporator	and	were	weighed	and	placed	in	pre-
weighed	vials	prior	to	liquid	chromatography-mass	spectrometry	(LCMS)	and	cytotoxicity	
sample	preparation	and	for	storage.		
	
	
2.4.3.	Liquid	Chromatography-Mass	Spectrometry	
	
Each	extract	obtained	was	diluted	in	filtered	ethanol	to	obtain	a	concentration	of	100	µg/mL	
filtered	ethanol	and	150	µg/mL	filtered	ethanol	for	LCMS	analysis.	500	µL	of	each	sample	
solution	was	placed	in	an	LCMS	vial	for	analysis.				
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LC-MS	and	tandem	mass	spectrometry	(MS/MS)	analyses	were	done	at	the	Mass	
Spectrometry	Facility,	Centro	de	Química	Estrutural,	Instituto	Superior	Técnico,	
Universidade	de	Lisboa.	For	the	analyses	of	the	EtOAc	extracts,	the	HPLC	system	was	
equipped	with	a	Hamilton®	PRP-1	column	(2.1	x	150mm,	5µm,	25°C,	0.2	mL/min)	under	the	
following	conditions:	0-15	min,	gradient	elution	of	50-80%	MeCN	with	0.1%	(v/v)	formic	acid	
in	H2O;	15-30	min,	isocratic	elution	of	80%	MeCN	with	0.1%	(v/v)	formic	acid	in	H2O.	
Samples	were	analyzed	in	both	positive	and	negative	ionization	methods.		
	
	
2.4.4.	Tandem	Mass	Spectrometry	
	
Peaks	identified	from	the	LC-MS	chromatograms	and	spectra	were	analyzed	further	using	
MS/MS.	The	ions	of	these	selected	peaks	were	collided	with	a	neutral	atom	or	molecule	
during	collision-induced	dissociation	using	a	collision	energy	of	27	eV	to	obtain	fragment	
ions.	
	
Larger	fragment	ions	were	further	dissociated	and	collided	with	a	neutral	atom	or	molecule	
to	obtain	smaller	fragment	ions.	Both	the	m/z	ratios	of	the	fragment	ions	and	the	leaving	
groups	during	MS/MS	analysis	were	detected	until	a	third	stage	of	mass	spectrometry.		
Post-processing	of	the	chromatograms	and	spectra	was	done	using	Thermo	Xcalibur®	
software.	
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3. RESULTS	AND	DISCUSSION	
	
3.1.	Preliminary	Tests		
	
3.1.1.	Cytotoxicity	Screening	
	
Preliminary	testing	for	cytotoxicity	of	the	extracts	were	tested	using	MTT	(3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium	bromide)	assay	against	MCF7	breast	cancer	cells.	This	
MTT	assay	was	used	to	screen	the	extract	for	the	presence	of	bioactive	compounds.	Active	
metabolism	of	viable	cells	convert	MTT	into	the	purple-colored	formazan	and	upon	cell	
death,	this	ability	to	metabolize	to	MTT	is	lost.	Consequently,	color	formation	is	a	marker	of	
cell	viability.		
	
Cisplatin,	a	known	chemotherapeutic	drug,	has	been	used	as	a	positive	control.	It	has	shown	
anticancer	activity	against	various	types	of	tumors	such	as	bladder,	head	and	neck,	lung,	
ovarian	and	testicular	cancers	(Dasari	&	Tchounwou,	2014).	Its	United	States	Food	and	Drug	
Administration	(US	FDA)	approval	and	clinical	introduction	led	the	interest	on	the	success	of	
platinum	complexes	as	anticancer	drugs	(Kelland,	2007).		
	
Cisplatin	has	already	been	used	against	breast	cancer	cells	and	sometimes	used	in	
combination	with	other	drugs	such	as	taxanes,	vinca	alkaloids,	and	5-fluorouracil	for	its	
synergistic	and	effective	effects	as	well	as	to	minimize	cisplatin	resistance	(Prabhakaran,	
Hassiotou,	Blancafort,	&	Filgueira,	2013).	Moreover,	the	cisplatin-related	toxicities	are	dose-
dependent	(Florea	&	Büsselberg,	2011),	making	it	an	ideal	positive	control.	
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Figure	3.1	MTT	assay	results	of	the	aqueous	(water)	and	organic	(ethyl	acetate)	extracts.	
	
	
Figure	3.1	shows	the	cytotoxicity	results	of	the	aqueous	and	organic	extracts.	The	organic	
extract	exhibited	cytotoxicity	against	breast	cancer	cells.	An	increase	in	the	extract	
concentration	from	1	to	10	µg/mL	resulted	to	an	increase	of	cytotoxicity	from	9%	to	23%,	
respectively.		
	
On	the	other	hand,	the	aqueous	extract	strangely	exhibited	negative	cytotoxicity,	that	is,	
there	were	more	live	breast	cancer	cells	in	the	treated	cells	than	that	of	in	the	control	cells.	
Increasing	the	extract	concentration	from	1	to	10	µg/mL	resulted	to	a	decrease	in	
cytotoxicity	from	–10%	to	–36%,	respectively.	Although	this	result	would	point	to	a	
proliferation	of	the	cancer	cells,	that	is	unlikely.	As	it	was	not	possible	to	repeat	the	
experiment	due	to	time	constraints	at	Hokudai,	a	similar	assay	is	being	performed	in	UAlg.		
	
It	should	be	noted	that	MTT	reduction	is	a	marker	for	cell	viability	and	not	specifically	for	
cell	proliferation,	although	MTT	reduction	is	often	used	to	measure	cell	proliferation.	With	
the	use	of	proper	controls,	however,	it	can	describe	cytotoxicity	and	cell	proliferation	
(Huyck,	Ampe,	&	Van	Troys,	2012).	Thus,	the	use	of	cisplatin	as	positive	control	for	the	
study.		Nevertheless,	bioactivity	was	observed	with	the	organic	extract.		
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Figure	3.2	MTT	assay	results	of	the	aqueous	fractions:	H1,	H2,	H3,	H4,	and;	organic	fractions:	E1,	E2,	E3.	
	
	
To	narrow	down	the	search	for	bioactive	compounds,	fractions	from	both	the	organic	and	
aqueous	extracts	were	tested	for	cytotoxicity.	Figure	3.2	shows	the	cytotoxicity	results	of	
the	fractions.	Aqueous	extract	fractions	consistently	exhibited	negative	cytotoxicity.	
However,	the	fractions	from	the	organic	extract	exhibited	varying	cytotoxicity	results.	
Fraction	E1,	like	the	aqueous	fractions,	exhibited	negative	cytotoxicity.	At	a	concentration	of	
1	µg/mL,	E2	exhibited	negative	cytotoxicity.	However,	at	a	concentration	of	10	µg/mL,	it	
exhibited	79%	cytotoxicity	indicative	of	the	presence	of	bioactive	compounds.	At	both	
concentrations	of	1	and	10	µg/mL,	fraction	E3	exhibited	cytotoxicity	at	58%	and	107%,	
respectively.	As	before,	a	negative	cytotoxicity	result	is	unclear	thus	necessitating	the	need	
repeat	these	results	and	conduct	further	cytotoxicity	tests.			
	
Nevertheless,	these	preliminary	cytotoxicity	results	narrow	down	the	search	for	the	
bioactive	compounds	in	the	organic	extract,	specifically	in	fractions	E2	and	E3.	
Consequently,	this	will	guide	the	search	for	bioactive	compounds	during	further	LC-MS	
analysis.		
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3.1.2.	Liquid	Chromatography-Mass	Spectrometry		
	
Aqueous	fractions	H1-H4	and	organic	fractions	E1-E3	were	separated	into	their	components	
by	means	of	LC-MS,	in	both	positive	and	negative	ionization	methods.		
	
LC-MS	chromatograms	for	aqueous	fractions	H1-H4	revealed	no	promising	peaks	in	both	
positive	and	negative	ionization	modes.	This,	together	with	the	cytotoxicity	screening	
results,	supported	the	move	to	focus	only	on	the	organic	fractions	for	the	search	of	
bioactive	compounds.		
	
There	were	also	no	significant	peaks	observed	from	the	organic	fractions	using	the	negative	
ionization	method.	Using	the	positive	ionization	method	for	the	organic	fraction,	however,	
yielded	some	notable	peaks,	as	shown	in	Figure	3.3	and	Figure	3.5,	which	are	reproducible	
as	shown	in	Figure	3.4	and	Figure	3.6,	respectively.		
	
	
Figure	3.3	Positive	ionization	LC-MS	chromatogram	of	fraction	E2.	
	
	
Figure	3.4	Reproducibility	of	peak	mass-to-charge	ratio	(m/z)	=	617.	
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Figure	3.5	Positive	ionization	LC-MS	chromatogram	of	fraction	E3.	
	
	
Figure	3.6	Reproducibility	of	peak	m/z	=	607.	
	
	
These	peaks	were	then	matched	in	the	MarinLit®	database	for	identification.	A	compound	
search	in	the	database	yielded	no	results.	This	implies	that	these	peaks	are	compounds	
which	have	not	yet	been	isolated	nor	recorded	in	the	database	and	consequently,	may	be	
novel	compounds.		
	
	
3.2.	Results	from	the	University	of	Algarve	
	
3.2.1.	Liquid	Chromatography-Mass	Spectrometry		
	
A	similar	procedure	for	LC-MS	analysis	was	done	the	at	the	Mass	Spectrometry	Facility,	
Centro	de	Química	Estrutural,	Instituto	Superior	Técnico,	Universidade	de	Lisboa,	this	time	
using	a	Hamilton®	PRP-1	column.	The	column	used	during	the	preliminary	tests,	Cadenza®	
CD-C18,	is	ideal	for	isomer	separation	and	impurities	detection.	In	addition,	the	selectivity	of	
this	column	is	ideal	for	small	molecule	pharmaceutical	testing	or	drugs	of	abuse.	However,	
the	number	of	peaks	and	compounds	identified	using	this	column	suggests	that	there	could	
be	another	column	which	can	better	separate	the	extracts.		
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The	problem	with	C18	columns	is	that	labile	compounds	can	be	irreversibly	bound	to	the	
silanol	groups	present.	Having	no	silanol	groups	present,	using	a	Hamilton	PRP-1	column	
eliminates	this	problem	since	Hamilton	polymers	are	made	entirely	of	polystyrene-
divinylbenzene.	Recovery	and	quantification	of	labile	and	reactive	compounds	is	enhanced.	
Moreover,	unlike	silica-based	C18	columns,	PRP-1	has	no	stationary	coating	thereby	
maintaining	its	performance	characteristics	longer	(ChromTech,	2017).	
	
This	change	of	column	resulted	to	the	identification	of	significant	peaks	in	both	positive	and	
negative	ionization	modes.	Figure	3.7	shows	the	LC-MS	total	ion	chromatogram	of	fraction	
E2	in	negative	ionization	mode	while	Error!	Reference	source	not	found.	shows	the	LC-MS	
total	ion	chromatogram	in	positive	ionization	mode.		
	
Several	peaks	have	been	identified.	Some	of	the	peaks	identified	in	the	negative	ionization	
mode	were:	retention	time	(RT)	=	4.23	minutes,	m/z	=	586.04	(Figure	3.8);	RT	=	5.38	min,	
m/z	=	612.12	(Figure	3.9);	RT	=	6.56	min,	m/z	=	565.99	(Figure	3.10),	m/z	=	613.97	(Figure	
3.11).	Additionally,	in	the	positive	ionization	mode:	RT	=	5.37	min,	m/z	=	568.26	(Figure	
3.13),	and;	RT	=	6.18	min,	m/z	=	225.20	(Error!	Reference	source	not	found.).		
	
	
Figure	3.7	Identified	peaks	from	the	LC-MS	total	ion	chromatogram	of	fraction	E2	in	negative	ionization	mode.	
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Figure	3.8	Mass	spectrum	with	peak	m/z	=	586,	RT	=	4.23	min.	
	
	
	
Figure	3.9	Mass	spectrum	with	peak	m/z	=	612,	RT	=	5.38	min.	
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Figure	3.10	Mass	spectrum	with	peak	m/z	=	566,	RT	=	6.56	min.	
	
	
	
Figure	3.11	Mass	spectrum	with	peak	m/z	=	614,	RT	=	6.56	min.	
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Figure	3.12	Identified	peaks	from	the	LC-MS	total	ion	chromatogram	of	fraction	E2	in	positive	ionization	mode.	
	
	
	
	
	
Figure	3.13	Mass	spectrum	with	peak	m/z	=	568,	RT	=	5.37	min.	
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3.2.2.	Tandem	Mass	Spectrometry		
	
Peaks	of	interest	were	identified	and	served	as	precursor	ions	during	tandem	mass	
spectroscopy	to	begin	the	structure	elucidation	process,	where	the	fragment	ions	help	give	
an	idea	of	the	structure	of	the	compound.	Three	stages	of	tandem	mass	spectrometry	were	
performed	to	better	separate	the	fragment	ions.		
	
During	the	first	stage	of	mass	spectrometry	(MS),	the	ion	source	formed	ions	and	were	
separated	according	to	their	mass-to-charge	ratio.	The	ions	formed	for	a	specific	mass-to-
charge	ratio,	served	as	the	precursor	ion	during	the	second	stage	of	mass	spectrometry	
(MS2).	The	second	stage	of	mass	spectrometry	involved	the	creation	of	fragment	ions	from	
the	precursor	ion.	The	fragment	ions	produced	from	MS2	were	then	selected,	and	if	
possible,	were	further	separated	into	smaller	fragment	ions	during	the	third	stage	of	mass	
spectrometry	(MS3).	
	
The	leaving	group	from	MS2	is	the	difference	between	the	precursor	ion	and	the	fragment	
ion	from	MS2.	Similarly,	the	leaving	group	from	MS3	is	the	difference	between	the	fragment	
ion	from	MS2	and	fragment	ion	from	MS3.	Leaving	groups	from	the	precursor	ions	provide	
information	on	the	functional	groups	or	the	fragment	of	the	precursor	ion	which	can	easily	
be	detached.		
	
The	m/z	values	of	the	peaks	identified	were	compared	to	previously	isolated	and	identified	
natural	products	from	other	marine	bryozoans.	Being	of	the	same	genus,	natural	products	
from	Cryptosula	pallasiana	were	compared.	The	alkaloids	isolated	from	Cryptosula	
pallasiana,	shown	in	Figure	1.10,	do	not	match	with	any	of	the	m/z	data	from	this	study.	
Further	search	of	similar	natural	products	showed	that	the	peak	with	m/z	=	566	might	be	
similar	with	that	of	an	alkaloid	isolated	from	the	New	Zealand	bryozoan	Pterocella	
vesiculosa	(Prinsep,	2008),	specifically	pterocellin	E,	shown	in	Figure	3.14.	
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Figure	3.14	Structure	and	pertinent	properties	of	pterocellin	E.	
	
Using	pterocellin	E	as	a	basis	for	structure,	structures	for	the	identified	peaks	are	proposed,	
as	well	as	the	fragment	ions	and	leaving	groups.		
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3.2.2.1	Peak	m/z	=	566	
	
The	selected	fragment	ion	from	MS2	for	m/z	=	566	(Figure	3.15)	is	shown	in	Figure	3.16,	and	
was	further	fragmented	through	MS3,	shown	in	Figure	3.17.	The	proposed	structures	of	the	
precursor	ion,	fragment	ions,	and	the	leaving	groups	are	shown	in	Figure	3.30.	
	
	
Figure	3.15	Precursor	ion.	Peak	m/z	=	566,	RT	=	6.56	min.	
	
Figure	3.16	Fragment	ion	after	MS2.	Peak	m/z	=	506.16,	RT	=	6.37	min.	
	
Figure	3.17	Fragment	ion	after	MS3.	Peak	m/z	=	281.28,	RT	=	6.37.	
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	3.2.2.2	Peak	m/z	=	586	
	
The	selected	fragment	ion	from	MS2	for	m/z	=	586	(Figure	3.18)	is	shown	in	Figure	3.19,	and	
was	further	fragmented	through	MS3,	shown	in	Figure	3.20.	The	proposed	structures	of	the	
precursor	ion,	fragment	ions,	and	the	leaving	groups	are	shown	in	Figure	3.31.	
	
	
Figure	3.18	Precursor	ion.	Peak	m/z	=	586,	RT	=	4.23	min.	
	
Figure	3.19	Fragment	ion	after	the	MS2.	Peak	m/z	=	526.02,	RT	=	4.52	min.	
	
Figure	3.20	Fragment	ion	after	the	MS3.	Peak	m/z	=	301.24,	RT	=	4.22.	
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3.2.2.3	Peak	m/z	=	612	
	
The	selected	fragment	ion	from	MS2	for	m/z	=	612	(Figure	3.21)	is	shown	in	Figure	3.22,	and	
was	further	fragmented	through	MS3,	shown	in	Figure	3.23.	The	proposed	structures	of	the	
precursor	ion,	fragment	ions,	and	the	leaving	groups	are	shown	in	Figure	3.32.	
	
	
Figure	3.21	Precursor	ion.	Peak	m/z	=	612,	RT	=	5.38	min.	
	
Figure	3.22	Fragment	ion	after	the	MS2.	Peak	m/z	=	526.02,	RT	=	4.52	min.	
	
Figure	3.23	Fragment	ion	after	the	MS3.	Peak	m/z	=	301.24,	RT	=	4.22	min.	
		 43	
3.2.2.4	Peak	m/z	=	614	
	
The	selected	fragment	ion	from	MS2	for	m/z	=	614	(Figure	3.24)	is	shown	in	Figure	3.25,	and	
was	further	fragmented	through	MS3,	shown	in	Figure	3.26.	The	proposed	structures	of	the	
precursor	ion,	fragment	ions,	and	the	leaving	groups	are	shown	in	Figure	3.33.	
	
	
Figure	3.24	Precursor	ion.	Peak	m/z	=	614,	RT	=	6.56	min.	
	
Figure	3.25	Fragment	ion	after	the	MS2.	Peak	m/z	=	552.98,	RT	=	5.74	min.	
	
Figure	3.26	Fragment	ion	after	the	MS3.	Peak	m/z	=	328.24,	RT	=	5.89	min.	
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3.2.2.5	Peak	m/z	=	568	
	
The	selected	fragment	ion	from	MS2	for	m/z	=	614	(Figure	3.27)	is	shown	in	Figure	3.28,	and	
was	further	fragmented	through	MS3,	shown	in	Figure	3.29.	The	proposed	structures	of	the	
precursor	ion,	fragment	ions,	and	the	leaving	groups	are	shown	in	Figure	3.34.	
	
	
Figure	3.27	Precursor	ion.	Peak	m/z	=	568,	RT	=	5.37	min.	
	
Figure	3.28	Fragment	ion	after	the	MS2.	Peak	m/z	=	550.33,	RT	=	5.44	min.	
	
Figure	3.29	Fragment	ion	after	the	MS3.	Peak	m/z	=	491.15,	RT	=	5.43	min.
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Peak	566	(neg)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
	
	
	
	
	
Figure	3.30	Proposed	structure	for	peak	m/z	=	566	and	its	fragment	ions	and	leaving	groups.	
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Chemical Formula: C29H24N4O5 
Exact Mass: 508.1747 
Molecular Weight: 508.5340 
m/z: 508.1747 (100.0%), 509.1780 (31.4%), 510.1814 
(2.7%), 510.1814 (2.0%), 509.1717 (1.5%), 510.1789 
(1.0%) 
Elemental Analysis: C, 68.49; H, 4.76; N, 11.02; O, 15.73 
	
Chemical Formula: C31H26N4O7 
Exact Mass: 566.1801 
Molecular Weight: 566.5700 
m/z: 566.1801 (100.0%), 567.1835 (33.5%), 568.1869 
(2.7%), 568.1869 (2.7%), 567.1772 (1.5%), 568.1844 
(1.4%) 
Elemental Analysis: C, 65.72; H, 4.63; N, 9.89; O, 19.77 
Chemical Formula: C17H18N2O2 
Exact Mass: 282.1368 
Molecular Weight: 282.3430 
m/z: 282.1368 (100.0%), 283.1402 (18.4%), 284.1435 
(1.6%) 
Elemental Analysis: C, 72.32; H, 6.43; N, 9.92; O, 11.33 
	
O
OH
Leaving group: 60 
Chemical Formula: C2H4O2 
Exact Mass: 60.02 
Molecular Weight: 60.05 
m/z: 60.02 (100.0%), 61.02 (2.2%) 
Elemental Analysis: C, 40.00; H, 6.71; O, 53.28 
N
N
O
O
H3C
O
Leaving group: 225 
Chemical Formula: C12H8N2O3 
Exact Mass: 228.0535 
Molecular Weight: 228.2070 
m/z: 228.0535 (100.0%), 229.0568 (13.0%) 
Elemental Analysis: C, 63.16; H, 3.53; N, 12.28; O, 21.03 
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Peak	586	(neg)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
	
	
	
	
	
	
Figure	3.31	Proposed	structure	for	peak	m/z	=	586	and	its	fragment	ions	and	leaving	groups.	
Chemical Formula: C30H35N5O4 
Exact Mass: 529.2689 
Molecular Weight: 529.6410 
m/z: 529.2689 (100.0%), 530.2723 (32.4%), 531.2756 
(2.7%), 531.2756 (2.4%), 530.2659 (1.8%) 
Elemental Analysis: C, 68.03; H, 6.66; N, 13.22; O, 12.08 
Chemical Formula: C32H37N5O6 
Exact Mass: 587.2744 
Molecular Weight: 587.6770 
m/z: 587.2744 (100.0%), 588.2777 (34.6%), 589.2811 
(5.8%), 588.2714 (1.8%), 589.2786 (1.2%) 
Elemental Analysis: C, 65.40; H, 6.35; N, 11.92; O, 16.33 
Chemical Formula: C17H23N3O2 
Exact Mass: 301.1790 
Molecular Weight: 301.3900 
m/z: 301.1790 (100.0%), 302.1824 (18.4%), 303.1857 
(1.6%), 302.1761 (1.1%) 
Elemental Analysis: C, 67.75; H, 7.69; N, 13.94; O, 10.62 
O
OH
Leaving group: 60 
Chemical Formula: C2H4O2 
Exact Mass: 60.02 
Molecular Weight: 60.05 
m/z: 60.02 (100.0%), 61.02 (2.2%) 
Elemental Analysis: C, 40.00; H, 6.71; O, 53.28 
Leaving group: 225 
Chemical Formula: C13H14N2O2 
Exact Mass: 230.1055 
Molecular Weight: 230.2670 
m/z: 230.1055 (100.0%), 231.1089 (14.1%) 
Elemental Analysis: C, 67.81; H, 6.13; N, 12.17; O, 13.90 
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Peak	612	(neg)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
	
	
	
	
	
	
Figure	3.32	Proposed	structure	for	peak	m/z	=	612	and	its	fragment	ions	and	leaving	groups.	
Chemical Formula: C32H37N5O4 
Exact Mass: 555.2846 
Molecular Weight: 555.6790 
m/z: 555.2846 (100.0%), 556.2879 (34.6%), 557.2913 
(5.8%), 556.2816 (1.8%) 
Elemental Analysis: C, 69.17; H, 6.71; N, 12.60; O, 11.52 
Chemical Formula: C34H39N5O6 
Exact Mass: 613.2900 
Molecular Weight: 613.7150 
m/z: 613.2900 (100.0%), 614.2934 (36.8%), 615.2967 
(6.6%), 614.2871 (1.8%), 615.2943 (1.2%) 
Elemental Analysis: C, 66.54; H, 6.41; N, 11.41; O, 15.64 
Chemical Formula: C19H25N3O2 
Exact Mass: 327.1947 
Molecular Weight: 327.4280 
m/z: 327.1947 (100.0%), 328.1980 (20.5%), 329.2014 
(2.0%), 328.1917 (1.1%) 
Elemental Analysis: C, 69.70; H, 7.70; N, 12.83; O, 9.77 
O
OH
Leaving group: 60 
Chemical Formula: C2H4O2 
Exact Mass: 60.02 
Molecular Weight: 60.05 
m/z: 60.02 (100.0%), 61.02 (2.2%) 
Elemental Analysis: C, 40.00; H, 6.71; O, 53.28 
Leaving group: 225 
Chemical Formula: C13H14N2O2 
Exact Mass: 230.1055 
Molecular Weight: 230.2670 
m/z: 230.1055 (100.0%), 231.1089 (14.1%) 
Elemental Analysis: C, 67.81; H, 6.13; N, 12.17; O, 13.90 
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Peak	614	(neg)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.33	Proposed	structure	for	peak	m/z	=	614	and	its	fragment	ions	and	leaving	groups.	
Chemical Formula: C33H40N4O4 
Exact Mass: 556.3050 
Molecular Weight: 556.7070 
m/z: 556.3050 (100.0%), 557.3083 (35.7%), 558.3117 
(3.5%), 558.3117 (2.7%), 557.3020 (1.5%) 
Elemental Analysis: C, 71.20; H, 7.24; N, 10.06; O, 11.50 
Chemical Formula: C35H42N4O6 
Exact Mass: 614.3104 
Molecular Weight: 614.7430 
m/z: 614.3104 (100.0%), 615.3138 (37.9%), 616.3171 
(7.0%), 615.3075 (1.5%), 616.3147 (1.2%) 
Elemental Analysis: C, 68.38; H, 6.89; N, 9.11; O, 15.62 
Chemical Formula: C20H28N2O2 
Exact Mass: 328.2151 
Molecular Weight: 328.4560 
m/z: 328.2151 (100.0%), 329.2184 (21.6%), 330.2218 
(2.2%) 
Elemental Analysis: C, 73.14; H, 8.59; N, 8.53; O, 9.74 
O
OH
Leaving group: 60 
Chemical Formula: C2H4O2 
Exact Mass: 60.02 
Molecular Weight: 60.05 
m/z: 60.02 (100.0%), 61.02 (2.2%) 
Elemental Analysis: C, 40.00; H, 6.71; O, 53.28 
Leaving group: 225 
Chemical Formula: C13H14N2O2 
Exact Mass: 230.1055 
Molecular Weight: 230.2670 
m/z: 230.1055 (100.0%), 231.1089 (14.1%) 
Elemental Analysis: C, 67.81; H, 6.13; N, 12.17; O, 13.90 
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Peak	568	(pos)	
	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
	
	
	
	
	
	
Figure	3.34	Proposed	structure	for	peak	m/z	=	566	and	its	fragment	ions	and	leaving	groups.
Chemical Formula: C31H25N4O6+ 
Exact Mass: 549.18 
Molecular Weight: 549.56 
m/z: 549.18 (100.0%), 550.18 (33.5%), 551.18 (5.4%), 
550.17 (1.5%), 551.18 (1.2%) 
Elemental Analysis: C, 67.75; H, 4.59; N, 10.20; O, 17.47 
Chemical Formula: C31H28N4O7+ 
Exact Mass: 568.20 
Molecular Weight: 568.59 
m/z: 568.20 (100.0%), 569.20 (33.5%), 570.20 (2.7%), 
570.20 (2.7%), 569.19 (1.5%), 570.20 (1.4%) 
Elemental Analysis: C, 65.49; H, 4.96; N, 9.85; O, 19.70 
Chemical Formula: C29H23N4O4+ 
Exact Mass: 491.17 
Molecular Weight: 491.53 
m/z: 491.17 (100.0%), 492.17 (31.4%), 493.18 (2.7%), 
493.18 (2.0%), 492.17 (1.5%) 
Elemental Analysis: C, 70.86; H, 4.72; N, 11.40; O, 13.02 
O
OH
Leaving group: 18 
 
Leaving group: 59 
Chemical Formula: C2H4O2 
Exact Mass: 60.02 
Molecular Weight: 60.05 
m/z: 60.02 (100.0%), 61.02 (2.2%) 
Elemental Analysis: C, 40.00; H, 6.71; O, 53.28 
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4. CONCLUSIONS	
	
This	study	aimed	to	identify	and	isolate	secondary	metabolites	from	the	bryozoan	
Cryptosula	zavjalovensis	from	Hokkaido,	Japan.	There	have	been	no	previous	studies	on	the	
natural	products	from	this	bryozoan	species	and	these	compounds	are	of	interest	for	their	
bioactivity.	Specifically,	it	aimed	to	determine	if	these	compounds	are	bioactive	and	if	this	
bioactivity	might	translate	into	medicinal	and	pharmaceutical	applications	through	
cytotoxicity	testing.	
	
From	these	objectives,	it	can	be	concluded	from	this	study	that:	
	
Secondary	metabolites	similar	to	that	of	pterocellin	E	have	been	identified.	The	elucidation	
of	the	structure	of	these	compounds,	however,	are	still	at	the	early	stages	using	tandem	
mass	spectrometry	and	are	thus	not	definitive.	The	structures	proposed	are	based	merely	
on	the	similarities	of	the	properties	of	the	identified	compounds	and	that	of	pterocellin	E.	
Further	tests	that	can	be	used	to	elucidate	the	structure	include	Infrared	(IR)	spectroscopy	
and	carbon-13	nuclear	magnetic	resonance	(13C	NMR)	to	identify	functional	groups	and	
proton	nuclear	magnetic	resonance	(H	NMR)	to	identify	molecular	fragments.	
	
Compounds	extracted	from	Cryptosula	zavjalovensis	are	bioactive.	The	cytotoxicity	
screening	showed	that	the	bioactive	compounds	are	contained	in	the	organic	extract,	
specifically	in	fractions	E2	and	E3.	At	a	concentration	of	1	µg/mL	fraction	E3	exhibited	58%	
cytotoxicity	while	at	a	concentration	of	10	µg/mL	fraction	E2	exhibited	79%	cytotoxicity	
whereas	E3	exhibited	107%	cytotoxicity	against	MCF-7	breast	cancer	cells.	In	order	to	better	
understand	the	bioactivity	and	cytotoxicity	of	these	extracts,	it	is	suggested	that	further	
cytotoxicity	tests	should	be	done	on	other	cell	lines.	
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